Felodipine


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Hypertension Initial: 5 mg daily. Individualised dose may be adjusted based on patient response. Usual dose: 2.5-10 mg daily. Angina pectoris Initial: 5 mg daily, may increase to 10 mg daily as necessary.
Administration
May be taken with or without food. Take w/o food or w/ a light meal. Avoid grapefruit juice.
Contraindications
Decompensated heart failure, acute myocardial infarction, unstable angina pectoris, significant cardiac valvular obstruction, cardiac outflow obstruction. Pregnancy.
Special Precautions
Patient with pronounced gingivitis/periodontitis, severe aortic stenosis, heart failure, hypertrophic cardiomyopathy with outflow tract obstruction. Hepatic impairment. Elderly. Lactation. Patient Counselling This drug may cause dizziness, fatigue, nausea and headache, if affected, do not drive or operate machinery. Monitoring Parameters Monitor blood pressure and heart rate. Assess for development of peripheral oedema.
Adverse Reactions
Significant: Tachycardia, myocardial ischaemia, peripheral oedema, angina, rarely, hypotension with or without syncope. Cardiac disorders: Palpitations. Gastrointestinal disorders: Nausea, abdominal pain, vomiting, mild gingival hyperplasia. General disorders and administration site conditions: Fatigue. Investigations: Very rarely, increased hepatic enzymes. Nervous system disorders: Headache, dizziness. Vascular disorders: Flushing.
Drug Interactions
Increased plasma concentrations with CYP3A4 inhibitors (e.g. cimetidine, erythromycin, itraconazole, ritonavir). Decrease plasma concentrations with CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin, barbiturates, efavirenz). May increase serum concentration of tacrolimus.
ATC Classification
C08CA02 - felodipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
Disclaimer: This information is independently developed by CIMS based on felodipine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in